Teladoc (TDOC) Form 144: Vested Shares to Be Sold on NYSE

Rhea-AI Filing Summary

Form 144 notice for Teladoc Health, Inc. (TDOC) shows a proposed sale of 12,846 common shares with an aggregate market value of $97,440.77 and an approximate sale date of 09/02/2025 on the NYSE. The filing reports the shares were acquired on 08/29/2025 through restricted stock vesting from the issuer and the payment nature is listed as compensation, indicating these are insider-awarded shares becoming eligible for sale.

The filing also discloses a sale by Mala Murthy of 13,856 shares on 06/02/2025 with gross proceeds of $95,052.16. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information about the issuer. Shares outstanding are reported as 176,690,662.

Positive

• Compliance disclosure: Form 144 filed with required details (acquisition date, amount, broker, proposed sale date).
• Small relative size: 12,846 shares represent a minimal portion of 176,690,662 shares outstanding, suggesting limited market impact.

Negative

• Insider sale: Shares awarded as compensation are being sold, which could be interpreted as insider liquidity rather than long-term holding.

Insights

Securities Analyst

TL;DR Routine insider sale filing for recently vested restricted shares; limited market impact given size relative to shares outstanding.

The filing documents a planned sale of 12,846 common shares valued at $97,440.77, acquired via restricted stock vesting on 08/29/2025 and slated for sale on 09/02/2025 on the NYSE. Because the shares arise from compensation vesting and the quantity represents a small fraction of the issuer's 176,690,662 shares outstanding, this is typically treated as a routine liquidity event rather than a signal of material company change. The prior transaction by Mala Murthy on 06/02/2025 is disclosed and consistent with individual selling activity. No financial performance or forward-looking operational details are included in the notice.

Corporate Governance Expert

TL;DR Form 144 properly reports planned insider sale of vested awards; disclosure aligns with Rule 144 procedural requirements.

The filing provides required information: acquisition date, nature of acquisition (restricted stock vesting), amount, proposed sale date, broker details, and the filer’s certification regarding material non-public information. From a governance perspective, the notice indicates compliance with resale notice obligations but contains no commentary on trading plans or 10b5-1 arrangements. The document does not allege any governance issues or regulatory concerns based solely on the disclosed items.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	12846	97440.77	176690662	09/02/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/29/2025	Restricted Stock Vesting	Issuer			12846	08/29/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mala Murthy 155 E 44th Street, Floor 17 New York NY 10017	Common	06/02/2025	13856	95052.16

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TDOC Form 144 filed for 09/02/2025 disclose?

The notice discloses a proposed sale of 12,846 common shares valued at $97,440.77, acquired via restricted stock vesting on 08/29/2025, with the sale to occur on 09/02/2025 on the NYSE.

Who acquired the shares and how were they acquired according to the filing?

The shares were acquired from the issuer through restricted stock vesting on 08/29/2025, and the nature of payment is listed as compensation.

What prior sales by the same person are disclosed in the Form 144?

The filing lists a prior sale by Mala Murthy of 13,856 common shares on 06/02/2025 with gross proceeds of $95,052.16.

How large is the company’s share base as reported in this filing?

The Form 144 reports 176,690,662 shares outstanding.

Does the Form 144 state any undisclosed material information about Teladoc Health?

No. The filer represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.